Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


QUOTED. 3 June 2019. US FDA.

Executive Summary

An expert panel recommended the US Food and Drug Administration down-classify certain absorbable collagen hemostatic devices despite concerns there isn't enough clinical data to support their safety and efficacy. See what the agency said in a briefing document here.

"In accordance with the 6-year rule, FDA considered data contained in two original PMAs approved for absorbable collagen-based hemostatic devices six or more years before the date of this panel to support our proposed classification recommendation." US Food & Drug Administration

Click here for a free trial of Medtech Insight


Related Content





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts